Dhruv S Kazi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6945982/publications.pdf

Version: 2024-02-01

		201658	138468
96	3,819	27	58
papers	citations	h-index	g-index

98	98	98	6160
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Thresholds for the costâ€“effectiveness of interventions: alternative approaches. Bulletin of the World Health Organization, 2015, 93, 118-124.	3.3	614
2	Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2016, 316, 743.	7.4	286
3	Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation, 2020, 141, 1214-1224.	1.6	147
4	Cardiovascular Deaths During the COVID-19ÂPandemic in the United States. Journal of the American College of Cardiology, 2021, 77, 159-169.	2.8	147
5	Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA - Journal of the American Medical Association, 2017, 318, 748.	7.4	130
6	Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly Adults. JAMA Cardiology, 2019, 4, 1084.	6.1	124
7	Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. Hypertension, 2021, 78, 1719-1726.	2.7	117
8	Beta-Blocker Therapy and Cardiac Events Among Patients With Newly Diagnosed Coronary Heart Disease. Journal of the American College of Cardiology, 2014, 64, 247-252.	2.8	113
9	Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap. Global Heart, 2015, 10, 111.	2.3	104
10	Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. BMJ: British Medical Journal, 2018, 363, k5094.	2.3	103
11	Association of Medicaid Expansion With Cardiovascular Mortality. JAMA Cardiology, 2019, 4, 671.	6.1	102
12	Association of Spontaneous Bleeding and Myocardial Infarction With Long-Term Mortality After Percutaneous CoronaryÂIntervention. Journal of the American College of Cardiology, 2015, 65, 1411-1420.	2.8	101
13	PCSK9 Inhibitors. Journal of the American College of Cardiology, 2017, 70, 2677-2687.	2.8	96
14	Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome. Annals of Internal Medicine, 2014, 160, 221-232.	3.9	84
15	Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. Circulation, 2017, 136, 1087-1098.	1.6	79
16	Association of Low Socioeconomic Status With Premature Coronary Heart Disease in US Adults. JAMA Cardiology, 2020, 5, 899.	6.1	79
17	Validation of Prediction Models for Critical Care Outcomes Using Natural Language Processing of Electronic Health Record Data. JAMA Network Open, 2018, 1, e185097.	5.9	72
18	Racial and Ethnic Disparities in Heart and Cerebrovascular Disease Deaths During the COVID-19 Pandemic in the United States. Circulation, 2021, 143, 2346-2354.	1.6	70

#	Article	IF	Citations
19	Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. JAMA Cardiology, 2021, 6, 1406.	6.1	68
20	Variation in Quality of Urgent Health Care Provided During Commercial Virtual Visits. JAMA Internal Medicine, 2016, 176, 635.	5.1	61
21	Cost-Effectiveness of Alirocumab. Annals of Internal Medicine, 2019, 170, 221.	3.9	57
22	Statins for Primary Prevention of Cardiovascular Disease. Medical Clinics of North America, 2017, 101, 689-699.	2.5	53
23	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Network Open, 2021, 4, e2114501.	5.9	49
24	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels. JAMA Internal Medicine, 2016, 176, 107.	5.1	41
25	Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D. JAMA Cardiology, 2019, 4, 828.	6.1	40
26	Angina and associated healthcare costs following percutaneous coronary intervention: A realâ€world analysis from a multiâ€payer database. Catheterization and Cardiovascular Interventions, 2016, 88, 1017-1024.	1.7	36
27	Cost-effectiveness of Low-density Lipoprotein Cholesterol Levelâ€“Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. JAMA Cardiology, 2019, 4, 969.	6.1	30
28	Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. The Lancet Global Health, 2019, 7, e1346-e1358.	6.3	30
29	Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. BMJ Open, 2019, 9, e027432.	1.9	30
30	PrEParing to End the HIV Epidemic â€” Californiaâ€™s Route as a Road Map for the United States. New England Journal of Medicine, 2019, 381, 2489-2491.	27.0	28
31	Association of Homelessness with Hospital Readmissionsâ€”an Analysis of Three Large States. Journal of General Internal Medicine, 2020, 35, 2576-2583.	2.6	28
32	Comparative Effectiveness of Clopidogrel in Medically Managed Patients With Unstable Angina and Nonâ€“ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 2249-2257.	2.8	27
33	Diabetes Screening by Race and Ethnicity in the United States: Equivalent Body Mass Index and Age Thresholds. Annals of Internal Medicine, 2022, 175, 765-773.	3.9	27
34	Quality Measure Development and Associated Spending by the Centers for Medicare & Medicaid Services. JAMA - Journal of the American Medical Association, 2020, 323, 1614.	7.4	26
35	Public health aspects of the worldâ€™s largest mass gathering: The 2013 Kumbh Mela in Allahabad, India. Journal of Public Health Policy, 2016, 37, 411-427.	2.0	25
36	Medicare Part D Plansâ€™ Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease. JAMA Internal Medicine, 2017, 177, 585.	5.1	25

#	Article	IF	Citations
37	Association Between County-Level Change in Economic Prosperity and Change in Cardiovascular Mortality Among Middle-aged US Adults. JAMA - Journal of the American Medical Association, 2021, 325, 445.	7.4	24
38	Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops. Circulation, 2021, 143, 2384-2394.	1.6	24
39	Simulating Strategies for Improving Control of Hypertension Among Patients with Usual Source of Care in the United States: The Blood Pressure Control Model. Journal of General Internal Medicine, 2015, 30, 1147-1155.	2.6	23
40	Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D. JAMA Internal Medicine, 2020, 180, 1696.	5.1	23
41	Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement. Circulation, 2020, 142, 203-213.	1.6	23
42	Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults. Journal of the American College of Cardiology, 2021, 78, 1954-1964.	2.8	23
43	The Economics of Heart Failure. Heart Failure Clinics, 2013, 9, 93-106.	2.1	22
44	Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans. JAMA Cardiology, 2017, 2, 1164.	6.1	22
45	Using Mobile Health Intervention to Improve Secondary Prevention of Coronary Heart Diseases in China: Mixed-Methods Feasibility Study. JMIR MHealth and UHealth, 2018, 6, e9.	3.7	22
46	Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, , 1-10.	4.9	22
47	Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitors in Heart Failure. Cardiology Clinics, 2008, 26, 1-14.	2.2	20
48	Using mobile technology to optimize disease surveillance and healthcare delivery at mass gatherings: a case study from India's Kumbh Mela. Journal of Public Health, 2016, 39, 616-624.	1.8	19
49	Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 1777-1785.	2.9	19
50	Generalizability of Clinical Trials Supporting the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. JAMA Internal Medicine, 2020, 180, 795.	5.1	17
51	Impact of polysubstance use on high-sensitivity cardiac troponin I over time in homeless and unstably housed women. Drug and Alcohol Dependence, 2020, 217, 108252.	3.2	16
52	Development of a mobile phone-based intervention to improve adherence to secondary prevention of coronary heart disease in China. Journal of Medical Engineering and Technology, 2016, 40, 372-382.	1.4	15
53	Case 18-2020: A 73-Year-Old Man with Hypoxemic Respiratory Failure and Cardiac Dysfunction. New England Journal of Medicine, 2020, 382, 2354-2364.	27.0	15
54	Hypertension testing and treatment in Uganda and Kenya through the SEARCH study: An implementation fidelity and outcome evaluation. PLoS ONE, 2020, 15, e0222801.	2.5	13

#	Article	IF	Citations
55	Characteristics of Populations Excluded From Clinical Trials Supporting Intensive Blood Pressure Control Guidelines. Journal of the American Heart Association, 2021, 10, e019707.	3.7	13
56	Rural-Urban Disparities In All-Cause Mortality Among Low-Income Medicare Beneficiaries, 2004â€“17. Health Affairs, 2021, 40, 289-296.	5.2	12
57	Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Quality and Outcomes, 2021, 14, e007521.	2.2	12
58	Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008477.	3.9	12
59	Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside. Progress in Cardiovascular Diseases, 2019, 62, 406-413.	3.1	10
60	From Innovation to Implementation. Journal of the American College of Cardiology, 2014, 64, 2616-2618.	2.8	9
61	Scaling Up Pharmacist-Led Blood Pressure Control Programs in Black Barbershops: Projected Population Health Impact and Value. Circulation, 2021, 143, 2406-2408.	1.6	9
62	Establishment of a cardiac telehealth program to support cardiovascular diagnosis and care in a remote, resource-poor setting in Uganda. PLoS ONE, 2021, 16, e0255918.	2.5	9
63	Cost-Effectiveness of Screening Ultrasound after a First, Febrile Urinary Tract Infection in Children Age 2-24ÂMonths. Journal of Pediatrics, 2020, 216, 73-81.e1.	1.8	8
64	Underperformance of Contemporary Phase III Oncology Trials and Strategies for Improvement. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1072-1078.	4.9	8
65	Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, CIRCOUTCOMES121007979.	2.2	7
66	Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults. Journal of the American Heart Association, 2022, 11, e025192.	3.7	7
67	Warfarin, Genes, and the (Health Care) Environment. JAMA Internal Medicine, 2014, 174, 1338.	5.1	6
68	Rising above the rhetoric: mobile applications and the delivery of cost-effective cardiovascular care in resource-limited settings. Future Cardiology, 2015, 11, 1-4.	1.2	6
69	Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 273-279.	4.0	6
70	The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice. Current Cardiology Reports, 2021, 23, 163.	2.9	6
71	Costâ€effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. Journal of the International AIDS Society, 2021, 24, e25690.	3.0	5
72	Days at Home After Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients. JAMA Cardiology, 2022, 7, 110.	6.1	5

#	Article	IF	Citations
73	Development and validation of an echocardiographic algorithm to predict long-term mitral and tricuspid regurgitation progression. European Heart Journal Cardiovascular Imaging, 2022, 23, 1606-1616.	1.2	5
74	A prospective cohort study examining exposure to incarceration and cardiovascular disease (Justice-Involved Individuals Cardiovascular Disease Epidemiology â€“ JUSTICE study): a protocol paper. BMC Public Health, 2022, 22, 331.	2.9	5
75	Cost-effectiveness and affordability of novel cardiovascular therapies: what physicians need to know. Heart, 2021, 107, 1267-1268.	2.9	4
76	A Delicate Balance. Journal of the American College of Cardiology, 2015, 65, 477-479.	2.8	3
77	Cost-effectiveness of PCSK9 Inhibitor Therapyâ€”Reply. JAMA - Journal of the American Medical Association, 2016, 316, 2152.	7.4	3
78	From Molecules to Markets. Circulation: Heart Failure, 2018, 11, e004815.	3.9	3
79	Who Is Rescuing Whom?. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005887.	2.2	3
80	Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice. JACC: Cardiovascular Interventions, 2021, 14, 2112-2123.	2.9	3
81	Infective endocarditis and antibiotic prophylaxis. Lancet, The, 2015, 386, 530.	13.7	2
82	Building the Economic Case for InvestmentÂin Cardiovascular Prevention. Journal of the American College of Cardiology, 2018, 71, 1090-1093.	2.8	2
83	Accurately Predicting Cardiovascular Riskâ€”and Acting on It. Annals of Internal Medicine, 2020, 172, 61.	3.9	2
84	Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: A registry-based data from a tertiary care center in Northern India. Indian Heart Journal, 2021, 73, 169-173.	0.5	2
85	Addressing the Last-Mile Problem in Blood Pressure Controlâ€”Scaling Up Community-Based Interventions. JAMA Health Forum, 2021, 2, e212022.	2.2	2
86	Evaluation of a Health Information Technologyâ€“Enabled Panel Management Platform to Improve Anticoagulation Control in a Low-Income Patient Population: Protocol for a Quasi-Experimental Design. JMIR Research Protocols, 2020, 9, e13835.	1.0	2
87	Cost-Effectiveness of Antibiotic-Eluting Envelope for Prevention of Cardiac Implantable Electronic Device Infections in Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, CIRCOUTCOMES121008443.	2.2	2
88	Informing the Choice of Direct Oral Anticoagulant Therapy in Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2021, 326, 2372.	7.4	2
89	Response by Kazi et al to Letter Regarding Article, â€œCost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathyâ€• Circulation, 2020, 142, e212-e213.	1.6	1
90	Prognosis of Claimsâ€•Versus Trialâ€Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. Journal of the American Heart Association, 2021, 10, e018744.	3.7	1

#	Article	IF	Citations
91	Patterns of Recovery in Cardiovascular Care after the COVID-19 Pandemic Surge. American Journal of the Medical Sciences, 2021, , .	1.1	1
92	Perspectives on Identifying and Treating Familial Hypercholesterolemia in Childhood. Clinical Chemistry, 2021, 67, 1312-1317.	3.2	1
93	Retrospective evaluation of echocardiographic variables for prediction of heart failure hospitalization in heart failure with preserved versus reduced ejection fraction: A single center experience. PLoS ONE, 2020, 15, e0244379.	2.5	1
94	The Value of Pharmacogenetic Testingâ€"Reply. JAMA Internal Medicine, 2015, 175, 314.	5.1	0
95	1788. Cost-Effectiveness of Penicillin Skin Testing Among Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy. Open Forum Infectious Diseases, 2018, 5, S506-S507.	0.9	0
96	Prevalence and Risk Factors for Preprocedural Medication Errors in Patients With Atrial Fibrillation and Atrial Flutter. Cardiology Research, 2021, 12, 265-268.	1.1	0